Search
lepodisiran
Indications:
- investigation treatment of elevated serum lipoprotein(a) cholesterol
Dosage:
- 4 mg to 608 mg SC
Mechanism of action:
- dose-dependent, long-duration reductions in serum lipoprotein(a) cholesterol
Interactions
drug adverse effects of anti-hyperlipidemic agents
General
short interfering double-stranded RNA; antisense oligonucleotide (siRNA, microRNA, miRNA)
anti-hyperlipidemic agent
References
- Nissen SE, Linnebjerg H, Shen X et al
Lepodisiran, an Extended-Duration Short Interfering RNA Targeting Lipoprotein(a).
A Randomized Dose-Ascending Clinical Trial.
JAMA. Published online November 12, 2023
PMID: 37952254 PMCID: PMC10641766 (available on 2024-05-12)
https://jamanetwork.com/journals/jama/fullarticle/2811935